126 hasil
Menampilkan 1–20 · 0,22 detik · RSS
The Journal of Haemophilia Practice
Scopus
ISSN 2055-3390 · Sciendo · 126 artikel di indeks
-
Artikel Jurnal
Moving beyond limitations: A narrative review exploring the intersection of haemophilia and physical activity
Persons with haemophilia (PwH) have historically been advised to avoid physical activity (PA) to limit bleeding risk, leading many to adopt sedentary lifestyles. The paradigm shift in treatment for PwH toward prophylaxis with extended half-life factor concentrates and non-factor replacement therapy…
-
Artikel Jurnal
Clinical profile and outcome of children with haemophilia A: The Royal Hospital, Oman’s experience
Data on clinical characteristics and bleeding outcome of Omani children with haemophilia A (HA) is limited. This study aims to describe the clinical profile and outcome of Omani children with HA at the Royal Hospital from 2006 to 2019.
-
Artikel Jurnal
Occult hepatitis B virus infection in people with haemophilia in South Africa
Occult hepatitis B virus (HBV) infection (OBI) is defined as the presence of HBV DNA in the absence of HBV surface antigen (HBsAg) serological markers. Despite the high prevalence of HBV infection in many communities, OBI prevalence among people with haemophilia (PWH) remains poorly characterised…
-
Artikel Jurnal
Clinical outcomes and safety profile of emicizumab and other treatment options for the management of children and adults with severe haemophilia A in the UAE: A retrospective study at two tertiary hospitals
More data on the clinical outcomes of emicizumab and other treatment options would guide the appropriate positioning of these agents among haemophilia management approaches. The purpose of this study was to review the clinical outcomes of emicizumab prophylaxis and other treatment options in…
-
Artikel Jurnal
The intergenerational impact of the Contaminated Blood Scandal: a qualitative study
The Contaminated Blood Scandal (CBS) infected many people with haemophilia (PwH) with blood-borne diseases. While studies have focused on those directly affected, little is known about the intergenerational impact on their children and siblings. Many adult children were subject to multiple adverse…
-
Artikel Jurnal
Acquired Haemophilia A – A Clinician’s Nightmare: Case Report
Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the formation of inhibitory antibodies against endogenous Factor VIII (FVIII), interfering with its function. Though a rare disorder, with around 1.5 cases per million, it is more prevalent among the elderly. There…
-
Artikel Jurnal
From shared experience to sustained leadership: a community of practice study of haemophilia society stakeholders in India
Stakeholder-led organisations play a critical role in bridging gaps in care and advocacy. Understanding the lived experiences and contributions of core facilitators within these communities is essential to strengthen their impact.
-
Artikel Jurnal
“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
Historically people with haemophilia B (PwHB) have experienced adverse clinical outcomes including joint bleeds, pain and arthropathy. The current management of severe and moderate haemophilia B in the UK is largely through the use of factor replacement therapy often given as prophylaxis. Despite…
-
Artikel Jurnal
Use of extended half-life factor IX products in the surgical setting: case series from a UK haemophilia centre
For people with haemophilia, surgical procedures, whether haemophilia-related or for other conditions, are associated with a risk of bleeding. Factor activity levels must be maintained for any invasive intervention. Clinical studies have shown that extended half-life (EHL) recombinant factor…
-
Artikel Jurnal
CATCH 2024 meeting summary: Collaborate & Address Treatment Challenges in Haemophilia
Greater treatment choice and the associated flexibility in regimens has necessitated new conversations with people with haemophilia about their personal goals. Innovations in haemophilia treatment drive the need for innovation in care service delivery. Supported by Sobi™, CATCH (Collaborate &…
-
Artikel Jurnal
Exploring the psychosocial status and lived experiences of haemophilia carriers: a comprehensive mixed methods study
Haemophilia carriers (HCs) face psychosocial challenges, including emotional distress, health concerns, and pregnancy-related issues. Understanding their needs is crucial for optimal healthcare support. This study examined the emotional impact on haemophilia carriers (HC).
-
Artikel Jurnal
Safety profile of concizumab: A systematic review and meta-analysis of randomised controlled trials
Concizumab's potential – A subcutaneous TFPI inhibitor for haemophilia, offering an alternative to intravenous therapySafety profile – Meta-analysis of RCTs shows no significant increase in adverse events compared to standard treatmentsSerious adverse events – Lower, though not statistically…
-
Artikel Jurnal
Results of a questionnaire for women with bleeding disorders at the Coagulation Unit, Karolinska University Hospital, Sweden
With correct diagnosis and treatment, women with bleeding disorders can live their lives without the pressure of having heavy menstrual bleeding (HMB) and the concern of postpartum bleeding, thus improving quality of life (QoL). As health care professionals (HCPs), we have the opportunity to…
-
Artikel Jurnal
Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
Prophylaxis is the global standard of care for haemophilia A (HA), and its adoption has been accelerated by wide use of emicizumab prophylaxis globally. Reports on the prophylaxis in people with haemophilia living in Africa are limited.
-
Artikel Jurnal
The impact of home therapy interventions on treatment adherence and patient independence in haemophilia management in Assam, India
Haemophilia is an inherited bleeding disorder requiring regular factor replacement therapy, often necessitating frequent hospital visits. Home therapy (HT) has emerged as a viable alternative, improving patient independence and adherence. This study evaluates the impact of a structured home therapy…
-
Artikel Jurnal
Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab
Emicizumab is a humanised, bispecific monoclonal antibody that bridges activated factor (F) IX and FX; it is approved for treatment of people with haemophilia A (PwHA) of all ages, with or without FVIII inhibitors. Qualitative experiences of PwHA switching to non-factor treatments, such as…
-
Artikel Jurnal
Severe haemophilia A with haemarthrosis improved on emicizumab: A case report
Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes…
-
Artikel Jurnal
Acquired haemophilia A: Balancing on the edge of haemostasis – Case series
Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective…
-
Artikel Jurnal
Incidence and prevention of post-immunisation bleeding complications in people with haemophilia at a treatment centre in India
Haemophilia is an inherited bleeding disorder characterised by a deficiency in coagulation factors, leading to an increased risk of bleeding, including after procedures such as immunisation. While immunisation is crucial for preventing infectious diseases, it poses a bleeding risk in people with…
-
Artikel Jurnal
Lessons from a qualitative study of treatment experiences and perceptions in people with haemophilia in France
Haemophilia A and B (HA/HB) are congenital, X-linked recessive bleeding disorders caused by deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. People with haemophilia (PwH) have increased risk of spontaneous or traumatic bleeding in joints, muscles, or soft tissues, which can be…